These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36293222)
1. Understanding the Radiobiological Mechanisms Induced by Delbart W; Karabet J; Marin G; Penninckx S; Derrien J; Ghanem GE; Flamen P; Wimana Z Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293222 [TBL] [Abstract][Full Text] [Related]
2. Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527 [TBL] [Abstract][Full Text] [Related]
3. Combined use of Fu J; Qiu F; Stolniceanu CR; Yu F; Zang S; Xiang Y; Huang Y; Matovic M; Stefanescu C; Tang Q; Wang F J Neuroendocrinol; 2022 Apr; 34(4):e13109. PubMed ID: 35304807 [TBL] [Abstract][Full Text] [Related]
4. Imaging DNA Damage Repair In Vivo After O'Neill E; Kersemans V; Allen PD; Terry SYA; Torres JB; Mosley M; Smart S; Lee BQ; Falzone N; Vallis KA; Konijnenberg MW; de Jong M; Nonnekens J; Cornelissen B J Nucl Med; 2020 May; 61(5):743-750. PubMed ID: 31757844 [TBL] [Abstract][Full Text] [Related]
5. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631 [TBL] [Abstract][Full Text] [Related]
7. Polish experience in Peptide receptor radionuclide therapy. Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of Zhang J; Song Q; Cai L; Xie Y; Chen Y J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025 [TBL] [Abstract][Full Text] [Related]
9. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]
10. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983 [TBL] [Abstract][Full Text] [Related]
12. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose. Arora G; Shukla J; Ghosh S; Maulik SK; Malhotra A; Bandopadhyaya G PLoS One; 2012; 7(3):e34019. PubMed ID: 22442740 [TBL] [Abstract][Full Text] [Related]
14. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor. Parghane RV; Basu S Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741 [TBL] [Abstract][Full Text] [Related]
15. King AP; Gutsche NT; Raju N; Fayn S; Baidoo KE; Bell MM; Olkowski CS; Swenson RE; Lin FI; Sadowski SM; Adler SS; Thiele NA; Wilson JJ; Choyke PL; Escorcia FE J Nucl Med; 2023 Apr; 64(4):549-554. PubMed ID: 36396453 [TBL] [Abstract][Full Text] [Related]